The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp1210
NEUROIMMUNE INTERACTIONS INVOLVED IN VISCERAL PAIN
Date
May 9, 2023
Explore related products in the following collection:
Abdominal pain is one of the most common reasons for doctors visits, and presents in numerous GI diseases. Unfortunately the current treatment options targeting sensory neurons to reduce pain have limited efficacy or unwanted side effects, and this is especially true for visceral pain. Recent evidence strongly suggests that non-neuronal cell populations found in the gut, including epithelial cells, enteric glia, immune cells and gut microbiota, play major roles in visceral pain by directly interacting with sensory neurons that carry pain information. In this session, you will learn about how these 'unusual suspects' (i.e., non-neuronal cell types) are involved in visceral pain processes and and how manipulating their activity reduces hypersensitivity, inflammation, and other GI disease outcomes.
Disorders of gut-brain interaction (DGBI), including irritable bowel syndrome (IBS) and functional dyspepsia (FD), are among the most common gastrointestinal (GI) disorders seen in primary care and GI practices. The pathophysiology is multifactorial and not well understood…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…